Yahoo Search Búsqueda en la Web

Entrar

Resultado de búsqueda

  1. www.ncbi.nlm.nih.gov › pmc › articlesDolutegravir Plus Lamivudine Two-Drug Regimen: Safety, Efficacy...

    29 de abr. de 2021 · The use of DTG-containing two-drug regimens (2DR), and, in particular, of DTG plus lamivudine (3TC), is one of the most promising solutions to the need to ease the management of HIV treatment without harming its efficacy and safety.

    • Valeria Cento, Carlo Federico Perno
    • 10.3390/diagnostics11050809
    • 2021
    • Diagnostics (Basel). 2021 May; 11(5): 809.

  2. clinicalinfo.hiv.gov › es › drugsDolutegravir / Lamivudina - Paciente | NIH - Clinicalinfo

    Cada tableta contiene: 50 mg dolutegravir. 300 mg lamivudina. Tome Dovato según las instrucciones de su proveedor de atención de salud. No deje de tomar ninguna dosis de Dovato, no cambie la dosis ni suspenda este medicamento sin hablar primero con su proveedor de atención de salud. Tómelo solo o con alimentos.

  3. en.wikipedia.org › wiki › DolutegravirDolutegravir/lamivudine/tenofovir - Wikipedia

    Dolutegravir/lamivudine/tenofovir (DTG/3TC/TDF) is a fixed-dose combination antiretroviral medication used to treat HIV/AIDS. It is a combination of dolutegravir, lamivudine, and tenofovir disoproxil.

  4. pubmed.ncbi.nlm.nih.gov › 34115650Dolutegravir/lamivudine as a first-line regimen in a test-and ...

    1 de oct. de 2021 · Objectives: Dolutegravir/lamivudine (DTG/3TC) is indicated for treatment-naive and experienced people with HIV; however, questions remain about its utility in a test-and-treat setting because of potential transmitted resistance and baseline hepatitis B virus (HBV) co-infection.

    • Charlotte-Paige Rolle, Mezgebe Berhe, Tulika Singh, Roberto Ortiz, Anson Wurapa, Moti Ramgopal, Pete...
    • 2021

  5. Imágenes

    • Thuốc Tdf/3TC/dtg giá bao nhiêu, mua ở đâu rẻ số 1 Việt Nam
    • DTG + 3TC FDC for Human Immunodeficiency Virus Infection Clinical Trial ...
    • Dolutegravir (DTG) Plus Lamivudine (3TC) Versus DTG Plus Tenofovir ...
    • SWITCHING TO DTG/3TC FIXED-DOSE COMBINATION (FDC) IS NON-INFERIOR TO ...
    • HIGH RATES OF VIROLOGIC SUPPRESSION WITH DTG/3TC IN NEWLY DIAGNOSED ...

    Ver todo

  6. pubmed.ncbi.nlm.nih.gov › 35079789Efficacy and Safety of Switching to Dolutegravir/Lamivudine ...

    29 de sept. de 2022 · Conclusions: Switching to DTG/3TC demonstrated noninferior and durable efficacy compared with continuing TAF-based regimens in treatment-experienced adults with HIV-1, with good safety and tolerability, and no resistance through 144 weeks.

  7. www.ncbi.nlm.nih.gov › pmc › articlesHIV Treatment with the Two-Drug Regimen Dolutegravir Plus ...

    24 de ago. de 2021 · The two-drug regimen dolutegravir plus lamivudine has demonstrated durable efficacy and a high barrier to resistance in phase III clinical trials with data up to 3 years, and this review summarizes data on the effectiveness and safety of dolutegravir plus lamivudine in real-world settings.

  8. pubmed.ncbi.nlm.nih.gov › 34983415Dolutegravir plus lamivudine versus efavirenz plus tenofovir ...

    4 de ene. de 2022 · DTG + 3TC could represent an optimal regimen for advanced patients. Clinical Trial Registration ChiCTR1900027640 (22/November/2019). Keywords: Dolutegravir; HIV; Lamivudine; Naive; Two-drug regimen. © 2021. The Author (s). Publication types. Observational Study. MeSH terms. Alkynes. Anti-HIV Agents* / adverse effects. Benzoxazines / adverse effects